LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.

Wall Street analysts remain bullish on Eli Lilly, boasting an Average Brokerage Recommendation (ABR) of 1.46, largely between ...

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...

Meadow Creek Wealth Advisors LLC decreased its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 7.7% during the ...

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Cash flow is valuable, but it’s not everything ...

Eli Lilly is grabbing investor attention thanks to sharp earnings and revenue growth projections, though its Zacks Rank ...

July kicks off the latter half of 2025, and the first six months of this year have been eventful, to say the least. Yet, the ...

Biocon share price gained 2.5 per cent after reports suggested that the company is planning to file for generic versions of ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...